Navigation Links
ARmark Authentication Technologies, LLC and Colorcon, Inc. Announce Alliance

GLEN ROCK, Pa., Nov. 9 /PRNewswire/ -- ARmark Authentication Technologies, LLC, and Colorcon, Inc. announced today an alliance in the development and introduction of ®mark® On-Dose ID(TM), an authentication technology that incorporates microscopic covert micro-tags into the immediate-release film coatings of solid oral dosage forms (SODFs) to prevent counterfeiting. The alliance provides Colorcon exclusive rights to market ARmark's micro-tags for tablet film coatings and to market this technology to pharmaceutical manufacturers globally.

(Photo: )

By leveraging the tablet coating expertise of Colorcon, a world leader in the manufacture and development of specialized film coatings, and ARmark's customized micro-tag authentication technology, the two companies collaborated to develop ®mark® On-Dose ID. The micro-tags are seamlessly integrated into existing tablet film coating processes without additional manufacturing steps or capital investments. By incorporating the micro-tags directly into a tablet's film coating, drug manufacturers achieve reliable placement on each and every tablet.

The customized micro-tags can hold significant amounts of brand-owner specific, encrypted information such as lot and batch ID numbers, logos and other text, patterns, shapes and symbols, in a particle the size of 75-110 microns, a space smaller than the diameter of a human hair. Nearly impossible to replicate or reverse engineer, the markers are compatible with other covert or overt identification technologies and can also be incorporated as part of labels, bottles, paper and blister packaging.

"The availability of this authentication technology is significant to drug manufacturers because adding ®mark® micro-tags to an existing immediate release film coated tablet can now be considered to be a SUPAC Level 1 annual reportable change," states Jeff Robertson, Director and General Manager at ARmark Authentication Technologies, LLC. "That means drug manufacturers can quickly begin using the On-Dose ID technology to protect their product without prior approval from the FDA."

®mark® covert marker technology has been available for more than two years in other markets, but the recent draft guidance issued by the Food and Drug Administration (FDA) regarding the use of physical chemical identifiers (PCIDs) defines how the commercial utilization of micro-tag technology can be used for on-dose authentication in the pharmaceutical industry. In accordance to the FDA's guidance document, ARmark manufactures the micro-tags from approved excipient materials generally regarded as safe (GRAS) or from the FDA's Inactive Ingredient Guide (IIG), under cGMP conditions.

According to Dr. Kamlesh Oza, Colorcon's General Manager of Film Coatings, "Colorcon's studies have shown there is no impact on dissolution or stability when the ®mark® On-Dose ID micro-tags are incorporated into an existing film-coated dosage form. This approach is in compliance to the FDA's guidance, enabling pharmaceutical companies to provide patients with safe security augmentation. As companies adopt this anticounterfeiting technology to quickly secure their brands, our studies will help them note the addition of micro-tags in their annual reports as required by the FDA."

The ®mark® On-Dose ID micro-tags are invisible to the naked eye once they are incorporated into a tablet film coating, but are easily identified with ®vision® optical viewing systems. These portable tools authenticate products by magnifying the micro-tags at any stage following the tablet coating process. The ®vision® system enables accurate, in-field detection within a matter of seconds without destroying the SODF sample.

Colorcon, Inc. is a world leader in the development, supply and technical support of fully formulated products for the pharmaceutical and dietary supplement industry. Its core businesses include film coatings, modified release technologies, functional excipients, and tablet branding services. Colorcon has 18 technical service laboratories globally and more than 1200 employees exclusively dedicated to its customer base. For more information on Colorcon capabilities and its products, call 215-699-7733 or visit

ARmark Authentication Technologies, LLC, based in Glen Rock, PA, develops custom authentication systems for brand protection, product surety and risk mitigation to fight global counterfeiting. Our technologies protect our clients' products with brand-owner-specific information so that the authenticity of these products becomes Indisputable. ARmark Authentication Technologies, LLC services a variety of industries, including but not limited to: pharmaceutical, medical devices, luxury goods, electronics, secure documents, food and apparel. ARmark Authentication Technologies, LLC is a wholly-owned subsidiary of Adhesives Research, Inc. For more information on ARmark Authentication Technologies, LLC and its products, call 1-717-227-5920 or visit

®mark® is a registered trademark and On-Dose ID(TM) is a trademark of ARmark Authentication Technologies, LLC. ARmark® is a registered trademark of Adhesives Research, Inc.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Jeff Robertson

SOURCE ARmark Authentication Technologies, LLC

SOURCE ARmark Authentication Technologies, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Leading Event for People With Disabilities on November 6-8 Features Latest Technologies, Products, Services, and More
2. BioStorage Technologies, Inc., Accelerates European Expansion with Opening of New German Facility
3. ReBuilder Medical Technologies, Inc. Hiring! Increases Staff by 40%
4. Blue Belt Technologies, Inc. Closes Series A Financing
5. ReBuilder Medical Technologies, Inc. Reports LOI With National DME Distributor
6. TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics
7. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)
8. Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Venous Ulcers
9. OxyBand Technologies, Inc. Hires a Leader in Medical Technology as Chief Technology Officer
10. Wound Management Technologies, Inc. Announces Evidence Based Study
11. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
Breaking Medicine Technology:
(Date:6/27/2016)... Brooklyn, NY (PRWEB) , ... June 27, 2016 ... ... is using cutting edge technology to revolutionize the emergency ambulance transport experience for ... Many are aware of how Uber has disrupted the taxi industry through the ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is ... a fitness app. The fitness app plans to fix the two major problems leading the ... one size fits all type program , They don’t eliminate all the reasons ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
Breaking Medicine News(10 mins):